Incidence of Depression in Patients with Chronic Hepatitis C Receiving Combination Therapy of Pegylated Interferon-Alpha and Ribavirin

Mahajan, Shalvi; Grover, Sandeep; Chawla, Yogesh

doi:10.1159/000358527

Cited by 6 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical profile of the study sample is also similar to that seen in previous studies from India [35][36][37] and studies from other parts of the world, which have evaluated psychosocial aspects of patients with HBV infection. 12,38 There is limited data on the prevalence of psychiatric disorders in patients with HBV infection and most studies have focused only on the assessment of anxiety and depression.…”

Section: Discussionsupporting

confidence: 69%

Psychiatric Morbidity, Fatigue, Stigma and Quality of Life of Patients With Hepatitis B Infection

Gupta

Chawla

Grover

2020

Journal of Clinical and Experimental Hepatology

Self Cite

View full text Add to dashboard Cite

Aims: This study aimed to evaluate the prevalence of psychiatric morbidity, fatigue, stigma and quality of life (QOL) of patients with hepatitis B infection. Additional aim of the study was to evaluate the correlates of psychiatric morbidity and QOL in patients with hepatitis B infection. Methods: A total of 150 patients with hepatitis B virus (HBV) infection (75 inactive carriers and 75 patients with chronic hepatitis) were evaluated on Mini International Neuropsychiatric Interview-PLUS, World Health Organization-QOL-BREF scale, Chronic Liver Disease Questionnaire, Toronto Chinese HBV Stigma Scale, HBV knowledge scale and Fatigue Severity scale. Results: About half of the study participants (49.3%) had at least one lifetime psychiatric morbidity and of these more than one-third (37.3%) fulfilled at least one current psychiatric diagnosis. Generalized anxiety disorder was seen in 19.3% of the participants. Major depressive disorder was the second most common psychiatric diagnosis fulfilled at the time of assessment, with nearly equal prevalence of first episode of depression (8%) and recurrent depressive disorder (7.3%). Compared to those with inactive hepatitis, patients in the chronic hepatitis group had poorer QOL and experienced more fatigue. However, both the groups did not differ in terms of knowledge and stigma. Compared to those without current or lifetime psychiatric diagnosis, those with current or lifetime psychiatric diagnosis had poorer QOL, higher level of stigma and higher fatigue scale. Conclusion: About half of the patients with HBV infection have psychiatric morbidity, which has negative impact on QOL of patients. Hence, it is important to recognize psychiatric morbidity among patients with HBV.

show abstract

Section: Discussionsupporting

confidence: 69%

Psychiatric Morbidity, Fatigue, Stigma and Quality of Life of Patients With Hepatitis B Infection

Gupta

Chawla

Grover

2020

Journal of Clinical and Experimental Hepatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The administration of LPS to humans may affect mood and elevate anxiety, while increasing peripheral levels of several cytokines [49] . Indeed, the infusion of inflammatory cytokines is arguably good evidence that cytokines contribute to depression as depressive symptoms are observed clinically with the therapeutic administration of interferon [50,51] .…”

Section: Microbiota and Gut-derived Inflammation In Mddmentioning

confidence: 99%

Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities

Slyepchenko

Maes

Jacka

et al. 2016

Psychother Psychosom

211

136

View full text Add to dashboard Cite

Background: Persistent low-grade immune-inflammatory processes, oxidative and nitrosative stress (O&NS), and hypothalamic-pituitary-adrenal axis activation are integral to the pathophysiology of major depressive disorder (MDD). The microbiome, intestinal compositional changes, and resultant bacterial translocation add a new element to the bidirectional interactions of the gut-brain axis; new evidence implicates these pathways in the patho-aetiology of MDD. In addition, abnormalities in the gut-brain axis are associated with several chronic non-communicable disorders, which frequently co-occur in individuals with MDD, including but not limited to irritable bowel syndrome (IBS), chronic fatigue syndrome (CFS), obesity, and type 2 diabetes mellitus (T2DM). Methods: We searched the PubMed/MEDLINE database up until May 1, 2016 for studies which investigated intestinal dysbiosis and bacterial translocation (the ‘leaky gut') in the pathophysiology of MDD and co-occurring somatic comorbidities with an emphasis on IBS, CFS, obesity, and T2DM. Results: The composition of the gut microbiota is influenced by several genetic and environmental factors (e.g. diet). Several lines of evidence indicate that gut-microbiota-diet interactions play a significant pathophysiological role in MDD and related medical comorbidities. Gut dysbiosis and the leaky gut may influence several pathways implicated in the biology of MDD, including but not limited to immune activation, O&NS, and neuroplasticity cascades. However, methodological inconsistencies and limitations limit comparisons across studies. Conclusions: Intestinal dysbiosis and the leaky gut may constitute a key pathophysiological link between MDD and its medical comorbidities. This emerging literature opens relevant preventative and therapeutic perspectives.

show abstract

“…Additionally, the next-generation antidepressant ketamine has been shown to decrease depressive symptoms via a decrease in circulating IL-1β levels ( Tan et al, 2017 ), a protein known to cause neuroinflammation and depressive behaviors ( Dunn et al, 2005 ; Dunn, 2006 ; Swiergiel and Dunn, 2007 ; Ransohoff and Brown, 2012 ). Conversely, anti-inflammatory drugs have been shown to enhance recovery in patients with depression ( Mendlewicz et al, 2006 ; Muller et al, 2006 ), and depressive symptoms are observed clinically with the administration of IFNs ( Baranyi et al, 2013 ; Mahajan et al, 2014 ). IL-10 knockout mice displayed a decreased latency to immobility in a forced swim test as a measure of depression, which was rescued by the administration of IL-10 ( Mesquita et al, 2008 ) that is known to inhibit pro-inflammatory cytokine production ( Ledeboer et al, 2000 ).…”

Section: The Effect Of Gut Microbiota On Local and Circulating Inflam...mentioning

confidence: 99%

A Reciprocal Link Between Gut Microbiota, Inflammation and Depression: A Place for Probiotics?

Eltokhi

Sommer

2022

Front. Neurosci.

View full text Add to dashboard Cite

Depression is a severe mental disorder that places a significant economic burden on public health. The reciprocal link between the trillions of bacteria in the gut, the microbiota, and depression is a controversial topic in neuroscience research and has drawn the attention of public interest and press coverage in recent years. Mounting pieces of evidence shed light on the role of the gut microbiota in depression, which is suggested to involve immune, endocrine, and neural pathways that are the main components of the microbiota-gut-brain axis. The gut microbiota play major roles in brain development and physiology and ultimately behavior. The bidirectional communication between the gut microbiota and brain function has been extensively explored in animal models of depression and clinical research in humans. Certain gut microbiota strains have been associated with the pathophysiology of depression. Therefore, oral intake of probiotics, the beneficial living bacteria and yeast, may represent a therapeutic approach for depression treatment. In this review, we summarize the findings describing the possible links between the gut microbiota and depression, focusing mainly on the inflammatory markers and sex hormones. By discussing preclinical and clinical studies on probiotics as a supplementary therapy for depression, we suggest that probiotics may be beneficial in alleviating depressive symptoms, possibly through immune modulation. Still, further comprehensive studies are required to draw a more solid conclusion regarding the efficacy of probiotics and their mechanisms of action.

show abstract

Incidence of Depression in Patients with Chronic Hepatitis C Receiving Combination Therapy of Pegylated Interferon-Alpha and Ribavirin

Cited by 6 publications

References 4 publications

Psychiatric Morbidity, Fatigue, Stigma and Quality of Life of Patients With Hepatitis B Infection

Psychiatric Morbidity, Fatigue, Stigma and Quality of Life of Patients With Hepatitis B Infection

Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities

A Reciprocal Link Between Gut Microbiota, Inflammation and Depression: A Place for Probiotics?

Contact Info

Product

Resources

About